Samuel Salot

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

Jaafar Bennouna, Emmanuelle Bompas, Eve Marie Neidhardt et al. · Cancer Immunology Immunotherapy · 2008 · 237 citations · Full text

γ9δ2 T, Cancer Immunosurveillance, Innacell γδ™ +12

DNAX accessory molecule‐1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells

Olivier Toutirais, Florian Cabillic, Gaëlle Le Friec et al. · European Journal of Immunology · 2009 · 122 citations

Dnax Accessory Molecule‐1, Immunology, Immunologic Mechanism +16

IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human Vγ9Vδ2 T Cells for Adoptive Immunotherapy

Aurélie Thedrez, Christelle Harly, Alexis Morice et al. · The Journal of Immunology · 2009 · 65 citations

Large scale expansion of γ9δ2 T lymphocytes: Innacell γδ™ cell therapy product

Samuel Salot, Catherine Laplace, Soraya Saïagh et al. · Journal of Immunological Methods · 2007 · 42 citations

γ9δ2 T, Lymphocyte Development, Large Scale Expansion +7

Large scale expansion of Vγ9Vδ2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS “TCR γ/δ + T cell isolation kit”

Samuel Salot, Sylvain Bercegeay, Brigitte Dréno et al. · Journal of Immunological Methods · 2009 · 16 citations

Lymphocyte Development, Large Scale Expansion, Immune Regulation +10